Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells

Cancer Gene Therapy

Volumn 6, Issue 3, 1999, Pages 195-208

  Dessureault, Sophie ^a   Graham, Frank L ^b   Gallinger, Steven ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenovirus vectors; Costimulatory molecules; Human gene therapy; Natural killer cells; Tumor immunology

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2;

ADENOVIRUS; ARTICLE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; GENE; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE; NATURAL KILLER CELL;

ADENOVIRIDAE; ANTIGENS, CD28; ANTIGENS, CD80; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENES, MHC CLASS I; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0033127014     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700018     Document Type: Article

References (82)

1. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71: 1093-1102.
2. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
3. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 1994;54:5552-5555.
4. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA. 1993;90:5687-5690.
5. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 1994;54:6477-6483.
6. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
7. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res. 1994;54: 5420-5423.
8. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994;153: 421-428.
9. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 1995;55: 3598-3603.
10. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med. 1994;179:1205-1214.
11. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990;248:1349-1356.
12. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445-480.
13. Liu Y, Linsley PS. Costimulation of T-cell growth. Curr Opin Immunol. 1992;4:265-270.
14. Gimmi CD, Freeman GJ, Gribben JG, et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA. 1991;88:6575-6579.
15. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol. 1991;147: 2461-2466.
16. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356:607-609.
17. Moretta A, Pantaleo G, Lopez-Botet M, Moretta L. Involvement of T44 molecules in an antigen-independent pathway of T cell activation. Analysis of the correlations to the T cell antigen-receptor complex. J Exp Med. 1985;162: 823-838.
18. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA. 1989;86:1333-1337.
19. Walter H, Schepensn S, Van Wauvve J, de Boer M. Ligation of CD28 on resting T cells by its ligand B7 results in the induction of both Th1- and Th2-type cytokines. Eur Cytokine Netw. 1994;5:13-21.
20. Lanier LL, O'Fallon S, Somoza C, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995;154:97-105.
21. + T lymphocytes. J Immunol. 1992;148:1985-1992.
22. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 1989;244:339-343.
23. Norton SD, Zuckerman L, Urdahl KB, Shefner R, Miller J, Jenkins MK. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol. 1992;149:1556-1561.
24. Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med. 1995;182:1415-1421.
25. Cavallo F, Martin-Fontecha A, Bellone M, et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol. 1995;25:1154-1162.
26. Yeh KY, Pulaski BA, Woods ML, et al. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol. 1995;165:217-224.
27. Geldhof AB, Raes G, Bakkus M, Devos S, Thielemans K, De Baetselier P. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res. 1995;55:2730-2733.
28. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity. 1996;5:311-317.
29. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL. Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human NK leukemia cell line. J Immunol. 1992;149:1115-1123.
30. Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol. 1994;152:3361-3369.
31. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and -negative NK cells. J Immunol. 1989;143:3183-3191.
32. Dessureault S, Graham F, Gallinger S. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector. Ann Surg Oncol. 1996;3:317-324.
33. Dessureault S, Gallinger S. Allogeneic lymphocyte responses to B7-1-expressing human cancer cell lines. J Surg Res. 1996;64:42-48.
34. Gately MK. Synergy between recombinant IL-2 (rIL-2) and IL-2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol. 1986;136:1274-1282.
35. Wong HL, Wilson DE, Jenson JC, Familletti PC, Stremlo DL, Gately MK. Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol. 1988;111:39-54.
36. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
37. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 1990;87:6808-6812.
38. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 1991;173:869-879.
39. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-γ induction by NK cell stimulatory factor (NKSF/IL-12): role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992;148:92-98.
40. Chehimi J, Starr SE, Frank I, et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med. 1992;175:789-796.
41. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-882.
42. Perussia B, Chan SH, D'Andrea A, et al. NK cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-αβ+, TCR-γδ+ T lymphocytes, and NK cells. J Immunol. 1992;149:3495-3502.
43. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med. 1994;180:211-222.
44. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 (IL-12)) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177:1199-1204.
45. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today. 1993;14:335-338.
46. + T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260:547-549.
47. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153: 1697-1706.
48. De Wit D, Flemming CL, Harris JD, et al. IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL). Clin Exp Immunol. 1996;105:353-359.
49. Pappo I, Tahara H, Robbins PD, et al. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res. 1995;58: 218-226.
50. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood. 1994; 83:1323-1328.
51. Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 1995;55:4980-4987.
52. Zitvogel L, Robbins PD, Storkus WJ, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol. 1996;26:1335-1341.
53. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, Walker JM, eds. Methods in Molecular Biology: Gene Transfer and Expression Protocols. Clifton, NJ: The Humana Press Inc., 1991:109-128.
54. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
55. Jaffee EM, Dranoff G, Cohen LK, et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res. 1993;53:2221-2226.
56. Prince HM, Dessureault S, Gallinger S, et al. Efficient adenoviral-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance. Exp Hematol. 1998;26:27-36.
57. Myers RH. Classical and Modern Regression with Applications. Boston: Duxbury Press; 1990.
58. van den Ingh HF, Ruiter DJ, Griffioen G, van Muijen GN, Ferrone S. HLA antigens in colorectal tumours: low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer. 1987;55:125-130.
59. Moller P, Momburg F, Koretz K, et al. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res. 1991;51:729-736.
60. Concha A, Cabrera T, Ruiz-Cabello F, Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer. 1991;6:146-154.
61. Moller P, Mattfeldt T, Gross C, et al. Expression of HLA-A, -B, -C, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. Am J Pathol. 1989;135:73-83.
62. Moller P, Hammerling GJ. The role of surface HLA-A,B,C molecules in tumour immunity. Cancer Surv. 1992; 13:101-127.
63. Redondo M, Concha A, Oldiviela R, et al. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res. 1991;51:4948-4954.
64. 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer. 1990;62:289-295.
65. Natali PG, Nicotra MR, Bigotti A, et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA. 1989;86: 6719-6723.
66. Fleming KA, McMichael A, Morton JA, Woods J, McGee JO. Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer. J Clin Pathol. 1981;34:779-784.
67. Kabawat SE, Bast RC, Jr, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer. 1983;32:547-554.
68. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer. 1990;46:1029-1034.
69. Lopez-Nevot MA, Esteban F, Ferron A, et al. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric, and laryngeal carcinomas. Br J Cancer. 1989;59:221-226.
70. Zeh HJ, Hurd S, Storkus WJ, Lotze MT. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother. 1993;14:155-161.
71. Williams JM, Abbud-Filho M, Kelley VE, Strom TB. Interleukin-2 apparently upregulates its receptor and induces proliferation of various resting mononuclear leukocytes in the absence of antigen. Cell Immunol. 1985;94: 383-393.
72. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996;273:104-106.
73. Lanier LL. Natural killer cells: from no receptors to too many. Immunity. 1997;6:371-378.
74. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature. 1986;319: 675-678.
75. Vose BM. Quantitation of proliferative and cytotoxic precursor cells directed against human tumours: limiting dilution analysis in peripheral blood and at the tumour site. Int J Cancer. 1982;30:135-142.
76. Coulie PG, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R, Boon T. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer. 1992;50:289-297.
77. Mazzocchi A, Belli F, Mascheroni L, Vegetti C, Parmiani G, Anichini A. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer. 1994;58:330-339.
78. Addison CL, Gauldie J, Muller WJ, Graham FL. An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast cancer model. Int J Oncol. 1995;7:1253-1260.
79. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA. 1995;92:8522-8526.
80. Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther. 1996;7:333-342.
81. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1997;7: 1995-2002.
82. Cusack JC, Spitz FR, Nguyen D, Zhang W-W, Cristiano RJ, Roth JA. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther. 1996;3:245-249.